ストックスクリーナーアプリを入手
42.87
2.22%
0.93
前日終値:
$41.94
開ける：
$42.63
24時間の取引高:
1.07M
Relative Volume:
1.44
時価総額：
$1.60B
収益：
$272.30M
当期純損益:
$-5.14M
株価収益率:
-262.20
EPS:
-0.1635
ネットキャッシュフロー:
$42.76M
1週間 パフォーマンス:
+13.86%
1か月 パフォーマンス:
+38.74%
6か月 パフォーマンス:
-3.79%
1年 パフォーマンス:
+36.01%
1日の値動き範囲:
$41.25
$42.98
1週間の範囲:
$37.46
$42.98
52週間の値動き範囲:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
42.87 | 1.60B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | BTIG Research | Buy |
| 2025-06-10 | 開始されました | William Blair | Outperform |
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing - simplywall.st
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Yahoo Finance
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
What Harrow (HROW)'s VERKAZIA Re‑Launch in Pediatric VKC Means For Shareholders - Sahm
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Harrow Inc. Q1 2026 Earnings: Significant EPS Miss Triggers Stock DeclineBook Value Growth - newsline.com
HARROW INC (HROW) Stock Chart - ChartMill
What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target? - Insider Monkey
Harrow Health Inc stock (US4158581094): Ophthalmology player trades below analyst targets amid secto - AD HOC NEWS
Harrow Inc. (HROW) Q1 2026 Earnings: Significant Earnings Miss Despite Positive Stock ReactionPeak Earnings Alert - newsline.com
William Blair Maintains Harrow(HROW.US) With Buy Rating - Moomoo
Harrow Health Releases June 2026 Investor Presentation Update - TipRanks
Harrow files Regulation FD disclosure to furnish June 2026 corporate presentation - TradingView
Harrow (NASDAQ: HROW) posts June 2026 corporate investor presentation - Stock Titan
Top 5 Small Cap Stocks With Huge Growth Potential - Insider Monkey
Harrow Health earnings on deck: Can branded drugs offset California exit? - Investing.com Nigeria
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesProfit Cycle Analysis - thelegaladvocate.com
Harrow Inc. (HROW) Advances 2.79% as Stock Approaches Key ResistanceLow Vol ETF - thelegaladvocate.com
Harrow Inc. (HROW) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock RallyRevenue Per Share - thelegaladvocate.com
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Rises Despite LossesEarnings Revision Report - newsline.com
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference - GlobeNewswire
HROW Q1 2026 Earnings: EPS Misses Estimates Significantly as Company Navigates Operational ChallengesCapex Guidance - newsline.com
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 LossesWhat's Changed - simplywall.st
Harrow Inc. (HROW) Q1 2026 Earnings: Significant EPS Miss Amid Operational ChallengesOperating Margin Analysis - newsline.com
Harrow Inc. Q1 2026 Earnings: Pharmaceutical Firm Misses EPS Estimates by Wide MarginAnalyst Coverage Count - thelegaladvocate.com
Harrow Inc (HROW) Shares Surge 6.8% -- What GF Score of 82 Tells Investors - GuruFocus
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism - Insider Monkey
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold - Seeking Alpha
Harrow, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-05-19 - Seeking Alpha
Harrow director Lauren Silvernail buys $31,000 in company stock By Investing.com - Investing.com Nigeria
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com - Investing.com Nigeria
Harrow director Lauren Silvernail buys $31,000 in company stock - Investing.com India
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (H - GuruFocus
5 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Harrow director Adrienne Graves buys $31,070 in company stock - Investing.com
Harrow (HROW) director Adrienne Graves buys 1,000 shares at $31.07 - Stock Titan
Harrow (HROW) director purchases 1,000 common shares at $31.00 price - Stock Titan
Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook - MSN
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
11.23%
0.45%
大文字化:
|
ボリューム (24 時間):